Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05853861 · ClinicalTrials.gov registry record · NA
Promoting Early Intervention Timing and Attention to Language
A NA study of MONITOR and COACH, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- NA
- Development phase
- 140
- Enrollment target
- 2
- Study locations
NCT05853861: Recruiting NA study of MONITOR and COACH, sponsored by University of California, Los Angeles.
NCT05853861 is a NA study of MONITOR and COACH that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 140 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05853861, a NA study of MONITOR and COACH, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed study (PETAL: Promoting Early intervention Timing and Attention to Language) aims to determine the timing of intervention among infants with Increased Likelihood for Autism (ILA; at risk for autism by virtue of having an older sibling with autism) on communication and language outcomes at 24 months. Results of this study will determine when (9 vs 12 vs 15 months), and based on which measures (brain, language, or their combination) to augment parental support with a specialized parent-mediated coaching intervention for optimal outcomes on communication and language at 24 months. Children will be recruited at 6-8 months of age and will begin with entry assessments. All children will first begin with the MONITOR condition (using Ages \& Stages Questionnaire (ASQ-3) and activity cards. Then when the child is 9 months, they will be randomized to continue with MONITOR condition or COACH condition (incorporates JASPER intervention and Babble Bootcamp) after second set of assessments. There are a total of 6 assessment timepoints (6-8 months of age, 9 months of age, 12 months of age, 15 months of age, 18 months of age, and 24 months of age). At time points of 9months and 12 months, the child will be randomized to COACH or MONITOR conditions. Once the child is randomized to COACH condition, they will continue with that condition until they terminate the study at 24 months. At the 15 months timepoint, there will no longer be a randomization. Children that were in the MONITOR condition will change to the COACH condition until they terminate the study.
Primary Outcome
The MSEL provides expressive language scale T-scores. We will compare the changes in T-scores throughout the different time points, expecting improvement throughout each time point.
Interventions
- BEHAVIORAL JASPER
- BEHAVIORAL Babble Bootcamp
Study Locations (2)
California
- UCLA - Los Angeles
Massachusetts
- University of Massachusetts Medical Center - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-11-25 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
What NCT05853861 shows while recruiting
NCT05853861 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with MONITOR appearing as the primary indexed condition, and to 2 interventions - of which JASPER is the first listed.
NCT05853861 reports a single indexed study location in California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05853861 about?
NCT05853861 is a clinical study titled "Promoting Early Intervention Timing and Attention to Language". The proposed study (PETAL: Promoting Early intervention Timing and Attention to Language) aims to determine the timing of intervention among infants with Increased Likelihood for Autism (ILA; at risk for autism by virtue of having an older sibling with autism) on communication and language outcomes ...
What is the current status of trial NCT05853861?
This trial is currently recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2024-11-25. Estimated completion is 2028-06-30.
What conditions does trial NCT05853861 study?
This clinical trial studies the following conditions: MONITOR, COACH.
What interventions are being tested in trial NCT05853861?
The interventions under investigation include: JASPER (BEHAVIORAL), Babble Bootcamp (BEHAVIORAL).
Who is sponsoring clinical trial NCT05853861?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05853861 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05853861's enrollment target sits among peer trials
140 713th of 2000 higher than 1,281 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI